Led · Series B · Jan 2026

Founded in 2020, AutoGrab offers an artificial-intelligence platform that delivers real-time vehicle valuations, sourcing insights, and analytics, positioning itself as “a Bloomberg terminal for the auto industry.” The software identifies a car down to exact variant and market context within seconds, helping insurers, dealers, and fleet managers determine true market value and optimise transactions. The company already counts about 1,000 Australian dealerships as customers and is used by 90% of local motor insurers for total-loss settlements. Cofounders Chris Gardner and Daniel Werzberger split leadership duties, with Gardner spearheading the newly launched London office to drive European expansion while Werzberger oversees Australian operations. AutoGrab plans to channel new capital into growth across the UK, broader Europe, and the Asia-Pacific region, with an eye on complexities such as the influx of Chinese EV brands. Prior to its latest raise, the startup secured a US$5 million Seed round in 2022 and a US$7 million Series A in October 2023, reflecting steady investor confidence. The most recent funding valued the company at US$230 million, underscoring strong traction in both domestic and international markets.

Led · Equity · Dec 2025

Founded in 2017 by Claire and James Fuller, Hnry offers a platform that automatically handles invoicing, tax calculations, payments and compliance for sole traders so they can focus on their core work. The Wellington-based company operates in New Zealand, Australia and, as of this year, the United Kingdom. Hnry now processes nearly 1 percent of New Zealand’s total tax take, indicating deep local penetration. Its Australian market share has grown seven-fold since 2020, while its newly launched UK business is expanding six times faster than the combined Australasian markets. To date the firm has raised close to $100 million and plans to use new capital to accelerate international expansion and product development. Hnry’s value proposition centres on eliminating administrative burden for sole traders, a segment that seeks simplicity over traditional accounting software.

Led · Series A · Aug 2025

Avasa is developing the Avasa Coupler, a category‑defining device that enables safe, fast and standardized reconnection of micro‑arteries used in reconstructive microsurgery. The company has reached design freeze and built pre‑production units that achieved 100% success in chronic animal studies. Founder and CEO Dr. Nandoun Abeysekera is a clinician‑bioengineer and Avasa reports strong clinical demand—89% of the 100+ microsurgeons interviewed expressed strong interest. Founded in 2018 and based in Auckland, New Zealand, Avasa is completing verification testing and recruiting commercial leadership to build its go‑to‑market strategy. The company intends to use the new capital to progress through FDA clearance and to launch commercially within the next 18 months. Avasa, led by CEO and founder Dr. Nandoun Abeysekera, is an Auckland, New Zealand-based medical device company focused on innovating surgical procedures through implantable devices. The company’s core product targets reconstructive microsurgery to help patients who have suffered debilitating disease and deformity. Avasa raised $1.55M in funding and intends to use the proceeds to expand operations. The announcement lists participation from both new and existing investors. Dr. Abeysekera expects the scope of the company’s device to expand into other surgical fields, including organ transplants, cardiothoracic surgery, and vascular surgery. The coverage was reported by FInSMEs on 14 September 2023.

Led · Equity · Sep 2024

Re-Leased offers a property management platform that integrates the intelligence and capabilities of Credia AI with customers’ property, tenant, lease and accounts information. The company’s software centralizes lease and tenant management and accounting workflows for commercial real estate professionals. Re-Leased is Auckland, New Zealand–based and operates offices in Auckland, Dallas, London, Melbourne and Napier. Its technology manages over 350,000 leases globally for approximately 1,400 customers. The company plans to use the new funds to continue expansion efforts in the UK and US. It recently raised US$12.5M to support that growth and ongoing product development. Re-Leased offers a cloud-based platform that gives commercial property managers and landlords complete oversight of their operations. The company’s software targets automated, intelligent management of commercial property portfolios and is used by thousands of commercial real estate companies. Re-Leased was originally founded in New Zealand in 2013 and is now based in London, England, with offices across the UK, Australia, New Zealand, and the US. The team has grown to more than 150 employees, with 50 new hires in the past year. The company plans to use the new funding to drive growth in key international markets, invest in its core software platform, and launch new products and partnerships. No revenue figures were disclosed in the article.

Participated · Series A · Feb 2024

Miruku develops molecular farming technology that programs plant cells—primarily safflower—to produce dairy proteins and modify fatty acid profiles, aiming to replace animal-derived dairy ingredients. The company focuses on a B2B model and says it modifies both proteins and fats within the same plant while leveraging interactions between recombinant dairy casein and native plant proteins to increase usable seed yield. Since its 2022 seed raise, Miruku has reached several proof-of-concept milestones for its proprietary dairy seed system, tripled its team, and formed co-development relationships with food manufacturing partners. Miruku has expanded its footprint to Israel and Australia, selecting Australia for initial market entry and planning to explore a U.S. presence. The company announced a $5 million pre-Series A round, which it described as an up round, to accelerate crop development and advance market readiness. Miruku has partnered with CSIRO to take modified safflower varieties into field trials in Australia as part of its commercialization efforts. Miruku is developing an alternative-dairy technology that programs and breeds plant crops to express real dairy proteins and other molecules directly in plant cells, using sunlight as the energy source. Founded in 2020 by Amos Palfreyman, Ira Bing, Harjinder Singh and Oded Shoseyov, the founding team has experience in dairy and plant science. The company is developing its technology in labs and greenhouses and is working with corporate and R&D partners to scale and implement across geographies. Miruku contrasts its approach with precision fermentation and cell cultivation by producing dairy building blocks inside plants, which the company says can be more efficient than cows. The team acknowledges technical challenges in programming plants to express mammalian proteins while retaining structure and function, and uses computational biology and techno-economic analysis to model optimal expression levels. Miruku was self-funded for its first 18 months and has doubled headcount this year; it secured $2.4 million in seed funding to add technology staff, develop partnerships and accelerate development, targeting prototypes and proof-of-concept soon and commercial use of its proteins in two to three years.